{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:20:36Z","timestamp":1792131636191,"version":"4.4.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40273-025-01492-1","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:49:49Z","timestamp":1744850989000},"page":"741-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-651X","authenticated-orcid":false,"given":"Gautam","family":"Ramani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley C.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Lautsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"2","key":"1492_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/diseases6020038","volume":"6","author":"NS Lan","year":"2018","unstructured":"Lan NS, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases. 2018;6(2):38.","journal-title":"Diseases"},{"issue":"2","key":"1492_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.14797\/OCDF4453","volume":"17","author":"B Sarah","year":"2021","unstructured":"Sarah B, Ashrith G, Sandeep S. Evaluation, diagnosis, and classification of pulmonary hypertension. Methodist Debakey Cardiovasc J. 2021;17(2):86.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"2","key":"1492_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pcad.2012.07.003","volume":"55","author":"AB Waxman","year":"2012","unstructured":"Waxman AB. Exercise physiology and pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55(2):172\u20139.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"1492_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1474515111429649","volume":"11","author":"LA Matura","year":"2012","unstructured":"Matura LA, McDonough A, Carroll DL. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012;11(1):51\u201361.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"14","key":"1492_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425\u201336.","journal-title":"N Engl J Med"},{"issue":"Suppl 14","key":"1492_CR6","doi-asserted-by":"publisher","first-page":"S1789","DOI":"10.21037\/jtd.2019.08.54","volume":"11","author":"S Sahay","year":"2019","unstructured":"Sahay S. Evaluation and classification of pulmonary arterial hypertension. J Thorac Dis. 2019;11(Suppl 14):S1789.","journal-title":"J Thorac Dis"},{"issue":"38","key":"1492_CR7","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"2","key":"1492_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14797\/CBHS2234","volume":"17","author":"KN Qaiser","year":"2021","unstructured":"Qaiser KN, Tonelli AR. Novel treatment pathways in pulmonary arterial hypertension. Methodist Debakey Cardiovasc J. 2021;17(2):106.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"134","key":"1492_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1183\/09059180.00007214","volume":"23","author":"P Corris","year":"2014","unstructured":"Corris P, Degano B. Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation. Eur Respir Rev. 2014;23(134):488\u201397.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"1492_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00408-020-00375-w","volume":"198","author":"ZG Vazquez","year":"2020","unstructured":"Vazquez ZG, Klinger JR. Guidelines for the treatment of pulmonary arterial hypertension. Lung. 2020;198(4):581\u201396.","journal-title":"Lung"},{"key":"1492_CR11","doi-asserted-by":"crossref","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023;61(1).","DOI":"10.1183\/13993003.01347-2022"},{"key":"1492_CR12","doi-asserted-by":"crossref","unstructured":"Falak U, Lekhak K, Athar MW, et al. Risk assessment in pulmonary arterial hypertension (PAH) based on the simplified French model: a single centre experience. European Respiratory Society; 2021.","DOI":"10.1183\/13993003.congress-2021.PA3602"},{"issue":"1","key":"1492_CR13","first-page":"204589401881629","volume":"9","author":"S Studer","year":"2018","unstructured":"Studer S, Hull M, Pruett J, Koep E, Tsang Y, Drake W III. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. Pulm Circ. 2018;9(1):2045894018816294.","journal-title":"Pulm Circ."},{"issue":"1","key":"1492_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12890-022-01906-2","volume":"22","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Abdalla F, Casado Moreno I, et al. The economic burden of pulmonary arterial hypertension in Spain. BMC Pulm Med. 2022;22(1):105.","journal-title":"BMC Pulm Med"},{"key":"1492_CR15","doi-asserted-by":"publisher","first-page":"175346662199504","DOI":"10.1177\/1753466621995040","volume":"15","author":"F Exposto","year":"2021","unstructured":"Exposto F, Hermans R, Nordgren \u00c5, et al. Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. Ther Adv Respir Dis. 2021;15:1753466621995040.","journal-title":"Ther Adv Respir Dis"},{"key":"1492_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40273-015-0361-0","volume":"34","author":"S Gu","year":"2016","unstructured":"Gu S, Hu H, Dong H. Systematic review of the economic burden of pulmonary arterial hypertension. Pharmacoeconomics. 2016;34:533\u201350.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1492_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12218","volume":"13","author":"Y Tsang","year":"2023","unstructured":"Tsang Y, Panjabi S, Funtanilla V, et al. Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). Pulm Circ. 2023;13(2): e12218.","journal-title":"Pulm Circ."},{"key":"1492_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"Br Med J"},{"key":"1492_CR19","unstructured":"Government A. Pharmaceutical benefits scheme. https:\/\/www.pbs.gov.au\/pbs\/home."},{"key":"1492_CR20","unstructured":"Government C. CADTH. https:\/\/www.cadth.ca\/."},{"key":"1492_CR21","unstructured":"Review IfCaE. https:\/\/icer.org\/."},{"key":"1492_CR22","unstructured":"National Centre for Pharmacoeconomics I. https:\/\/www.ncpe.ie\/."},{"key":"1492_CR23","unstructured":"Excellence NIfHaC. https:\/\/www.nice.org.uk\/."},{"key":"1492_CR24","unstructured":"Consortium SM. https:\/\/www.scottishmedicines.org.uk\/home."},{"key":"1492_CR25","unstructured":"Group AWMS. https:\/\/awttc.nhs.wales\/."},{"key":"1492_CR26","unstructured":"EPPI-Centre. CCEMG-EPPI-Centre Cost Converter. https:\/\/eppi.ioe.ac.uk\/costconversion\/."},{"key":"1492_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-019-0945-0","volume":"19","author":"I-C Hwang","year":"2019","unstructured":"Hwang I-C, Cho G-Y, Choi H-M, et al. Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension. BMC Pulm Med. 2019;19:1\u201311.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1492_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12890-019-0989-1","volume":"19","author":"K Morrisroe","year":"2019","unstructured":"Morrisroe K, Stevens W, Sahhar J, et al. The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. BMC Pulm Med. 2019;19(1):226. https:\/\/doi.org\/10.1186\/s12890-019-0989-1.","journal-title":"BMC Pulm Med"},{"key":"1492_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijcard.2020.06.036","volume":"319","author":"A Chaturvedi","year":"2020","unstructured":"Chaturvedi A, Kanwar M, Chandrika P, Thenappan T, Raina A, Benza RL. National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations\u2014analysis of the National Inpatient Sample Database. Int J Cardiol. 2020;319:131\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2020.06.036.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1492_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.36469\/9812","volume":"5","author":"G Ruiz","year":"2018","unstructured":"Ruiz G, Yeaw J, Lickert CA, et al. Using real world evidence to describe pulmonary arterial hypertension treatment patterns, healthcare resource utilization, and costs associated with PDE-5 inhibitor monotherapy. J Health Econ Outcomes Res. 2018;5(2):206\u201319. https:\/\/doi.org\/10.36469\/9812.","journal-title":"J Health Econ Outcomes Res."},{"issue":"1","key":"1492_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s41669-023-00453-8","volume":"8","author":"HMG DuBrock","year":"2024","unstructured":"DuBrock HMG, Gauthier-Loiselle HD, Linder M, Satija J, Manceur A, Cloutier AM, Lefebvre M, Panjabi P, Frantz S, Frantz RP. Economic burden of delayed diagnosis in patients with pulmonary arterial hypertension (PAH). Pharmacoecon Open. 2024;8(1):133\u201346. https:\/\/doi.org\/10.1007\/s41669-023-00453-8.","journal-title":"Pharmacoecon Open."},{"issue":"12","key":"1492_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/crj.13704","volume":"17","author":"Y Tsang","year":"2023","unstructured":"Tsang Y, Stokes M, Kim YJ, Tilney R, Panjabi S. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: a retrospective cohort study. Clin Respir J. 2023;17(12):1209\u201322. https:\/\/doi.org\/10.1111\/crj.13704.","journal-title":"Clin Respir J"},{"issue":"7 Supplement","key":"1492_CR33","doi-asserted-by":"publisher","first-page":"S427","DOI":"10.1016\/j.jval.2022.04.720","volume":"25","author":"N Tassara","year":"2022","unstructured":"Tassara N, Virgilio F, Ketlun MV, Julian G, Balan D. EE472 use of resources and economic cost of the treatment of pulmonary arterial hypertension for the social security and private perspective of Argentina. Value Health. 2022;25(7 Supplement):S427. https:\/\/doi.org\/10.1016\/j.jval.2022.04.720.","journal-title":"Value Health."},{"issue":"8","key":"1492_CR34","first-page":"834","volume":"24","author":"CD Burger","year":"2018","unstructured":"Burger CD, Ozbay AB, Lazarus HM, et al. Treatment patterns and associated health care costs before and after treatment initiation among pulmonary arterial hypertension patients in the United States. J Manag Care Spec Pharm. 2018;24(8):834\u201342.","journal-title":"J Manag Care Spec Pharm"},{"key":"1492_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2466-12-75","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A, Edelsberg J, Teal S, Mychaskiw MA, Oster G. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulm Med. 2012;12:1\u20138.","journal-title":"BMC Pulm Med"},{"key":"1492_CR36","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3049","author":"H Pan","year":"2022","unstructured":"Pan H, Argula RG, Badesch DB, et al. Longitudinal effects of initiation of parenteral prostanoid therapy for the treatment of pulmonary arterial hypertension, the Pulmonary Hypertension Association Registry. Conference Abstract. Am J Respir Crit Care Med. 2022. https:\/\/doi.org\/10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3049.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4 Supplement","key":"1492_CR37","doi-asserted-by":"publisher","first-page":"A2337","DOI":"10.1016\/j.chest.2022.08.1927","volume":"164","author":"Y Tsang","year":"2022","unstructured":"Tsang Y, Kim Y, Tinley R, Stokes ME, Panjabi S. Impact of initiating selexipag within 12 months of pulmonary arterial hypertension diagnosis on hospitalization and health care costs. Chest. 2022;164(4 Supplement):A2337. https:\/\/doi.org\/10.1016\/j.chest.2022.08.1927.","journal-title":"Chest"},{"issue":"11","key":"1492_CR38","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1080\/13696998.2017.1363049","volume":"20","author":"R Dufour","year":"2017","unstructured":"Dufour R, Pruett J, Hu N, et al. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. J Med Econ. 2017;20(11):1178\u201386.","journal-title":"J Med Econ"},{"issue":"1","key":"1492_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12890-022-01906-2","volume":"22","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Abdalla F, Casado Moreno I, et al. The economic burden of pulmonary arterial hypertension in Spain. BMC Pulm Med. 2022;22(1):105. https:\/\/doi.org\/10.1186\/s12890-022-01906-2.","journal-title":"BMC Pulm Med"},{"key":"1492_CR40","unstructured":"Alvarez Albarr\u00e1n J, Pulido T, Valdez H, Cruz J, Sanchez-Guerra K, Morais A. Pulmonary arterial hypertension in Mexico: landscape of management and associated costs in the perspective of public healthcare institutions. In: Presented at: ISPOR Europe 2023. 2023."},{"key":"1492_CR41","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.jval.2020.08.494","volume":"23","author":"N Kim","year":"2020","unstructured":"Kim N, Farber HW, Highland K, et al. PCV3 hospitalization rates and association with survival risk at baseline in patients with pulmonary artery hypertension (PAH) receiving selexipag in real-world (RW) clinical practice. Conference Abstract. Value Health. 2020;23:S486. https:\/\/doi.org\/10.1016\/j.jval.2020.08.494.","journal-title":"Value Health."},{"issue":"Supplement","key":"1492_CR42","doi-asserted-by":"publisher","first-page":"S703","DOI":"10.1016\/j.jval.2020.08.1812","volume":"23","author":"PVS Souza","year":"2020","unstructured":"Souza PVS, Nacazume J, Lima PVP, et al. PRO76 pulmonary arterial hypertension in Brazil: treatment patterns and hospitalization based on primary research. Value Health. 2020;23(Supplement):S703.","journal-title":"Value Health."},{"key":"1492_CR43","doi-asserted-by":"publisher","first-page":"PA1195","DOI":"10.1183\/13993003.congress-2023.PA1195","volume":"62","author":"T Weiss","year":"2023","unstructured":"Weiss T, Ramey DR, Pham N, et al. End-of-life healthcare resource utilization and costs in patients with PAH: a real-world analysis. Eur Respir J. 2023;62:PA1195. https:\/\/doi.org\/10.1183\/13993003.congress-2023.PA1195.","journal-title":"Eur Respir J"},{"issue":"1","key":"1492_CR44","first-page":"101","volume":"29","author":"CD Burger","year":"2023","unstructured":"Burger CD, Wu B, Classi P, Morland K. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension. J Manag Care Spec Pharm. 2023;29(1):101\u20138.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1492_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3899\/jrheum.170307","volume":"45","author":"A Fischer","year":"2018","unstructured":"Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement. J Rheumatol. 2018;45(2):235\u201341.","journal-title":"J Rheumatol"},{"issue":"5","key":"1492_CR46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3111\/13696998.2012.690801","volume":"15","author":"R Copher","year":"2012","unstructured":"Copher R, Cerulli A, Watkins A, Laura MM. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ. 2012;15(5):947\u201355. https:\/\/doi.org\/10.3111\/13696998.2012.690801.","journal-title":"J Med Econ"},{"issue":"2","key":"1492_CR47","first-page":"94","volume":"5","author":"LA Durst","year":"2012","unstructured":"Durst LA, Carlsen J, Kuchinski M, et al. Impact of the removal of the monthly liver function test requirement for ambrisentan. Am Health Drug Benefits. 2012;5(2):94\u2013101.","journal-title":"Am Health Drug Benefits."},{"key":"1492_CR48","doi-asserted-by":"publisher","first-page":"175346661984377","DOI":"10.1177\/1753466619843774","volume":"13","author":"KB Highland","year":"2019","unstructured":"Highland KB, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. Baseline history of patients using selexipag for pulmonary arterial hypertension. Ther Adv Respir Dis. 2019;13:1753466619843774. https:\/\/doi.org\/10.1177\/1753466619843774.","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"1492_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40801-020-00183-x","volume":"7","author":"BB Dean","year":"2020","unstructured":"Dean BB, Saundankar V, Stafkey-Mailey D, et al. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020;7(3):229\u201339. https:\/\/doi.org\/10.1007\/s40801-020-00183-x.","journal-title":"Drugs Real World Outcomes."},{"key":"1492_CR50","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12913-014-0676-0","volume":"14","author":"M Sikirica","year":"2014","unstructured":"Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676. https:\/\/doi.org\/10.1186\/s12913-014-0676-0.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"1492_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.18553\/jmcp.2017.17228","volume":"24","author":"CD Burger","year":"2018","unstructured":"Burger CD, Pruett JA, Lickert CA, Berger A, Murphy B, Drake W 3rd. Prostacyclin use among patients with pulmonary arterial hypertension in the United States: a retrospective analysis of a large health care claims database. J Manag Care Spec Pharm. 2018;24(3):291\u2013302. https:\/\/doi.org\/10.18553\/jmcp.2017.17228.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"1492_CR52","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3111\/13696998.2013.849713","volume":"16","author":"S Johnson","year":"2013","unstructured":"Johnson S, Delate T, Boka A, Shaw P, Zager C. Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system. J Med Econ. 2013;16(12):1414\u201322.","journal-title":"J Med Econ"},{"issue":"6","key":"1492_CR53","first-page":"608","volume":"28","author":"A Ogbomo","year":"2022","unstructured":"Ogbomo A, Tsang Y, Mallampati R, Panjabi S. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022;28(6):608\u201316.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1492_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12090","volume":"12","author":"LN Pizzicato","year":"2022","unstructured":"Pizzicato LN, Nadipelli VR, Governor S, et al. Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States. Pulm Circ. 2022;12(2): e12090.","journal-title":"Pulm Circ."},{"issue":"4","key":"1492_CR55","doi-asserted-by":"publisher","first-page":"A2252","DOI":"10.1016\/j.chest.2021.07.1980","volume":"160","author":"P Classi","year":"2021","unstructured":"Classi P, Morland K, Wu B, et al. Health outcomes and costs associated with oral treprostinil and selexipag one year into treatment: a United States claims database analysis in patients with pulmonary arterial hypertension. Conference Abstract. Chest. 2021;160(4):A2252\u20133. https:\/\/doi.org\/10.1016\/j.chest.2021.07.1980.","journal-title":"Chest"},{"issue":"1 Part","key":"1492_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12190","volume":"13","author":"H Runheim","year":"2023","unstructured":"Runheim H, Kjellstr\u00f6m B, Beaudet A, et al. Societal costs associated with pulmonary arterial hypertension: a study utilizing linked national registries. Pulm Circ. 2023;13(1 Part): e12190. https:\/\/doi.org\/10.1002\/pul2.12190.","journal-title":"Pulm Circ."},{"key":"1492_CR57","doi-asserted-by":"crossref","unstructured":"Runheim RKB, Beaudet A, Ivarsson B, Husberg M, Pillai N, et al. Health care utilization and productivity loss associated with pulmonary arterial hypertension: a Swedish nationwide register study. 2022.","DOI":"10.1093\/eurheartj\/ehac544.2851"},{"issue":"3","key":"1492_CR58","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3111\/13696998.2012.665109","volume":"15","author":"Q Said","year":"2012","unstructured":"Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC. The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15(3):500\u20138. https:\/\/doi.org\/10.3111\/13696998.2012.665109.","journal-title":"J Med Econ"},{"issue":"48","key":"1492_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008503","volume":"96","author":"K Morrisroe","year":"2017","unstructured":"Morrisroe K, Stevens W, Sahhar J, et al. Quantifying the direct public health care cost of systemic sclerosis\u2014a comprehensive data linkage study. Medicina. 2017;96(48): e8503. https:\/\/doi.org\/10.1097\/MD.0000000000008503.","journal-title":"Medicina"},{"issue":"6","key":"1492_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217798","volume":"14","author":"NB Shah","year":"2019","unstructured":"Shah NB, Mitchell RE, Proctor ST, et al. High rates of medication adherence in patients with pulmonary arterial hypertension: an integrated specialty pharmacy approach. PLoS ONE. 2019;14(6): e0217798. https:\/\/doi.org\/10.1371\/journal.pone.0217798.","journal-title":"PLoS ONE"},{"issue":"3","key":"1492_CR61","doi-asserted-by":"publisher","first-page":"204589401986842","DOI":"10.1177\/2045894019868422","volume":"9","author":"M Corkish","year":"2019","unstructured":"Corkish M, Devine L, Clarke M, Murray B, Rose-Jones L. EXPRESS: rates of hospitalization associated with the use of aldosterone receptor antagonists in patients with pulmonary arterial hypertension. Pulm Circ. 2019;9(3):2045894019868422. https:\/\/doi.org\/10.1177\/2045894019868422.","journal-title":"Pulm Circ."},{"issue":"1","key":"1492_CR62","doi-asserted-by":"publisher","first-page":"204589401988008","DOI":"10.1177\/2045894019880086","volume":"10","author":"RP Frantz","year":"2020","unstructured":"Frantz RP, Hill JW, Lickert CA, et al. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. Pulm Circ. 2020;10(1):2045894019880086. https:\/\/doi.org\/10.1177\/2045894019880086.","journal-title":"Pulm Circ"},{"issue":"2","key":"1492_CR63","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1378\/chest.14-1004","volume":"147","author":"RP Frantz","year":"2015","unstructured":"Frantz RP, Schilz RJ, Chakinala MM, et al. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest. 2015;147(2):484\u201394. https:\/\/doi.org\/10.1378\/chest.14-1004.","journal-title":"Chest"},{"issue":"6","key":"1492_CR64","doi-asserted-by":"publisher","first-page":"608","DOI":"10.18553\/jmcp.2022.28.6.608","volume":"28","author":"A Ogbomo","year":"2022","unstructured":"Ogbomo A, Tsang Y, Mallampati R, Panjabi S. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022;28(6):608\u201316. https:\/\/doi.org\/10.18553\/jmcp.2022.28.6.608.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1492_CR65","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/13696998.2023.2204769","volume":"26","author":"E Papademetriou","year":"2023","unstructured":"Papademetriou E, Liu X, Beaudet A, Tsang Y, Potluri R, Panjabi S. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension. J Med Econ. 2023;26(1):644\u201355.","journal-title":"J Med Econ"},{"key":"1492_CR66","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.19197","author":"K Shankar","year":"2023","unstructured":"Shankar K, Ahmed I. Cardiopulmonary outcomes and disparities in long-term anticoagulant use in secondary pulmonary hypertension patients: a nationwide analysis. Conference Abstract. Circ Conf Am Heart Assoc. 2023. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.19197.","journal-title":"Circ Conf Am Heart Assoc."},{"issue":"2","key":"1492_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12325-014-0094-z","volume":"31","author":"M Small","year":"2014","unstructured":"Small M, Piercy J, Pike J, Cerulli A. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy. Adv Ther. 2014;31(2):168\u201379. https:\/\/doi.org\/10.1007\/s12325-014-0094-z.","journal-title":"Adv Ther"},{"issue":"1","key":"1492_CR68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.36469\/001c.35246","volume":"9","author":"C Song","year":"2022","unstructured":"Song C, Kunovszki P, Beaudet A. Comparison of healthcare encounters and drug persistence in patients with pulmonary arterial hypertension receiving oral selexipag, inhaled iloprost, or parenteral treprostinil: a retrospective database analysis. J Health Econ Outcomes Res. 2022;9(1):151\u201360. https:\/\/doi.org\/10.36469\/001c.35246.","journal-title":"J Health Econ Outcomes Res."},{"issue":"3","key":"1492_CR69","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-023-00547-z","volume":"10","author":"Y Tsang","year":"2023","unstructured":"Tsang Y, Singh R, Verma S, Panjabi S. Hospitalization among pulmonary arterial hypertension patients with and without connective tissue disease comorbidities prescribed oral selexipag. Rheumatol Ther. 2023;10(3):741\u201356.","journal-title":"Rheumatol Ther."},{"issue":"5","key":"1492_CR70","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1378\/chest.14-0193","volume":"146","author":"CD Burger","year":"2014","unstructured":"Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146(5):1263\u201373. https:\/\/doi.org\/10.1378\/chest.14-0193.","journal-title":"Chest"},{"issue":"6","key":"1492_CR71","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1016\/j.chest.2020.07.079","volume":"158","author":"V Anand","year":"2020","unstructured":"Anand V, Vallabhajosyula S, Cheungpasitporn W, et al. Inpatient palliative care use in patients with pulmonary arterial hypertension: temporal trends, predictors, and outcomes. Chest. 2020;158(6):2568\u201378. https:\/\/doi.org\/10.1016\/j.chest.2020.07.079.","journal-title":"Chest"},{"issue":"12","key":"1492_CR72","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.healun.2022.08.019","volume":"41","author":"JD Garry","year":"2022","unstructured":"Garry JD, Kolaitis NA, Kronmal R, Simon MA, De Marco T. Anticoagulation in pulmonary arterial hypertension\u2014association with mortality, healthcare utilization, and quality of life: the Pulmonary Hypertension Association Registry (PHAR). J Heart Lung Transplant. 2022;41(12):1808\u201318. https:\/\/doi.org\/10.1016\/j.healun.2022.08.019.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"1492_CR73","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1586\/14737167.2016.1120672","volume":"16","author":"W Thongsri","year":"2016","unstructured":"Thongsri W, Bussabawalai T, Leelahavarong P, et al. Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):525\u201336. https:\/\/doi.org\/10.1586\/14737167.2016.1120672.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"1492_CR74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11630780-000000000-00000","volume":"10","author":"A Roman","year":"2012","unstructured":"Roman A, Barber\u00e0 JA, Escribano P, et al. Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Appl Health Econ Health Policy. 2012;10(3):175\u201388. https:\/\/doi.org\/10.2165\/11630780-000000000-00000.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"1492_CR75","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1080\/13696998.2023.2254160","volume":"26","author":"J McConnell","year":"2023","unstructured":"McConnell J, Bilir SP, Xu Y, Tsang Y, Panjabi S. Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension. J Med Econ. 2023;26(1):1349\u201355. https:\/\/doi.org\/10.1080\/13696998.2023.2254160.","journal-title":"J Med Econ"},{"key":"1492_CR76","doi-asserted-by":"crossref","unstructured":"C. Villaquiran-Torres RD-V, A. Taborda-Restrepo KR-L, C. Chamorro-Vel\u00e1squez, Londo\u00f1o-Trujillo aD. Burden of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in a developing country (Colombia\u2014South America). 2021. p. A3730.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A3730"},{"key":"1492_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02684-x","author":"V Mclaughlin","year":"2023","unstructured":"Mclaughlin V, Alsumali A, Liu R, Klok R, Martinez EC, Nourhussein I, Bernotas D, Chevure J, Pausch C, De Oliveira Pena J, Lautsch D. Population health model predicting the long-term impact of sotatercept on morbidity and mortality in patients with pulmonary arterial hypertension (PAH). Adv Ther. 2023. https:\/\/doi.org\/10.1007\/s12325-023-02684-x.","journal-title":"Adv Ther"},{"issue":"7","key":"1492_CR78","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.015816","volume":"10","author":"A Tran-Duy","year":"2021","unstructured":"Tran-Duy A, Morrisroe K, Clarke P, et al. Cost-effectiveness of combination therapy for patients with systemic sclerosis-related pulmonary arterial hypertension. J Am Heart Assoc. 2021;10(7): e015816. https:\/\/doi.org\/10.1161\/jaha.119.015816.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1492_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221211","volume":"14","author":"E Bergot","year":"2019","unstructured":"Bergot E, De Leotoing L, Bendjenana H, et al. Hospital burden of pulmonary arterial hypertension in France. PLoS ONE. 2019;14(9): e0221211. https:\/\/doi.org\/10.1371\/journal.pone.0221211.","journal-title":"PLoS ONE"},{"issue":"12","key":"1492_CR80","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/03007995.2023.2174330","volume":"39","author":"R Jandhyala","year":"2022","unstructured":"Jandhyala R. Commercial impact of adding real-world evidence to clinical trials at regulatory approval: a Markovian-like transition model. Curr Med Res Opin. 2022;39(12):1559\u201366. https:\/\/doi.org\/10.1080\/03007995.2023.2174330.","journal-title":"Curr Med Res Opin"},{"key":"1492_CR81","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.jval.2021.04.1003","volume":"24","author":"H Phatak","year":"2021","unstructured":"Phatak H, Pena J, Patel K, Patel D. PRO18 a systematic literature review of the economic burden and cost drivers in pulmonary arterial hypertension. Value Health. 2021;24:S200\u20131.","journal-title":"Value Health."},{"issue":"1","key":"1492_CR82","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jval.2021.11.247","volume":"25","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Abdalla F, Moreno IC, et al. POSA103 estimation of the economic and social burden of pulmonary arterial hypertension in Spain. Value Health. 2022;25(1):S53.","journal-title":"Value Health."},{"key":"1492_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01427-2","author":"A Watzker","year":"2024","unstructured":"Watzker A, Alsumali A, Ferro C, et al. Economic burden associated with pulmonary arterial hypertension in the United States. Pharmacoeconomics. 2024. https:\/\/doi.org\/10.1007\/s40273-024-01427-2.","journal-title":"Pharmacoeconomics"},{"key":"1492_CR84","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00408-019-00289-2","volume":"198","author":"SL Wronski","year":"2020","unstructured":"Wronski SL, Mordin M, Kelley K, et al. The role of noninvasive endpoints in predicting long-term outcomes in pulmonary arterial hypertension. Lung. 2020;198:65\u201386.","journal-title":"Lung"},{"key":"1492_CR85","doi-asserted-by":"publisher","first-page":"A1079","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1079","volume":"209","author":"A Watzker","year":"2024","unstructured":"Watzker A, Ferro C, Diegues G, et al. Loss of productivity among commercially insured patients treated for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2024;209:A1079. https:\/\/doi.org\/10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1079.","journal-title":"Am J Respir Crit Care Med"},{"key":"1492_CR86","unstructured":"CADTH. Selexipag (Uptravi\u00ae). 2016. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0482_complete_Uptravi-Oct-28-16.pdf. Accessed 10 Nov 2023."},{"key":"1492_CR87","doi-asserted-by":"crossref","unstructured":"Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. ClinicoEcon Outcomes Res. 2017. p. 731\u201339.","DOI":"10.2147\/CEOR.S119117"},{"key":"1492_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-019-4422-5","volume":"19","author":"O Lilyasari","year":"2019","unstructured":"Lilyasari O, Subekti Y, Atika N, et al. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. BMC Health Serv Res. 2019;19:1\u20139.","journal-title":"BMC Health Serv Res"}],"updated-by":[{"DOI":"10.1007\/s40273-025-01518-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000}}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01492-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01492-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01492-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:38:59Z","timestamp":1757158739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01492-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01492-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40273-025-01518-8","asserted-by":"object"}]},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"23 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the copyright holder.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40273-025-01518-8","URL":"https:\/\/doi.org\/10.1007\/s40273-025-01518-8","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA (who manufacture sotatercept).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors disclose the following: this study was funded by Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA (who manufacture sotatercept). V.B. and H.B. are employees of Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA and may hold stock or stock options in Merck and Co., Inc., Rahway, NJ, USA. G.R. has received consulting fees from Merck and Co., Inc. and research funding from United Therapeutics. D.B., I.Z., and A.C.H. are employees of Adelphi Values PROVETM and were contracted by Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA, to carry out the study and to support with medical writing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets supporting the conclusions of this article are included within the article or supplementary material. The full datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All authors attest that they meet the ICMJE criteria for authorship. G.R. was involved in the interpretation of the data and the critical revision of the manuscript. V.B., H.B., and D.L. were involved in the study conception and design, data analysis, and critical revision of the manuscript. I.Z. and A.C.H. were involved in the study conception and design, data collection and analysis, and preparation and editing of the manuscript. D.B. was involved in the data collection and analysis and preparation and editing of the manuscript. All authors have read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}